Azaindoles

摘要

The invention is directed to compositions containing physiologically active compounds of general formula (I):-
wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z 1 R 8 , -C(=O)-NY 3 Y 4 , -CO 2 R 8 , -NY 3 Y 4 , -N(R 6 )-C(=O)-R 7 , -N(R 6 )-C(=O)-NY 3 Y 4 , -N(R 6 )-C(=O)-OR 7 , -N(R 6 )-SO 2 -R 7 , -N(R 6 )-SO 2 -NY 3 Y 4 and one or more halogen atoms; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -C(=O)-OR 5 or -C(=O)-NY 3 Y; and X 1 represents CH, C-halo, C-CN, C-R 7 , C-NY 3 Y 4 , C-OH, C-Z 2 R 7 , C-C(=O)-OR 5 , C-C(=O)-NY 3 Y 4 , C-N(R 8 )-C(=O)-R 7 , C-SO 2 -NY 3 Y 4 , C-N(R 8 )-SO 2 -R 7 , C-alkenyl, C-alkynyl or C-NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.